1. CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth
- Author
-
Neil I. Goldstein, John Mendelsohn, Marie Prewett, and Patricia Rockwell
- Subjects
Chimeric antibody ,Cancer Research ,Combination therapy ,business.industry ,medicine.drug_class ,Cetuximab ,Cancer ,Antineoplastic Agents ,Pharmacology ,Antibodies, Monoclonal, Humanized ,Monoclonal antibody ,medicine.disease ,ErbB Receptors ,Oncology ,Pharmacokinetics ,Neoplasms ,Animals ,Humans ,Medicine ,Tumor growth ,business ,Egfr tyrosine kinase - Abstract
Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human:murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval. Clin Cancer Res; 21(2); 227–9. ©2015 AACR. See related article by Goldstein et al., Clin Cancer Res 1995;1(11) November 1995;1311–8
- Published
- 2015
- Full Text
- View/download PDF